Albemarle Corporation, a diversified specialty chemicals manufacturing company, has solidified its position with a consistent dividend history spanning 32 years. Despite challenges reflected by negative payout ratios and fluctuating profitability metrics, the company maintains an admirable dividend yield of 2.15%. Investors should be cautious about the company's dividend growth, which shows moderate increment over the past years.
| Metric | Value |
|---|---|
| Sector | Chemicals |
| Dividend yield | 2.15% |
| Current dividend per share | $2.65 |
| Dividend history | 32 years |
| Last cut or suspension | None |
The consistency in Albion's dividend history, spanning over three decades, indicates an established payout strategy. This is a testament to their commitment to returning value to shareholders, despite recent financial strains.
| Year | Dividend per Share (USD) |
|---|---|
| 2025 | $1.215 |
| 2024 | $1.610 |
| 2023 | $1.600 |
| 2022 | $1.580 |
| 2021 | $1.560 |
Albemarle's modest dividend growth of 1.83% over the past 5 years reflects a cautious reiteration of shareholder value, signaling internal reinvestment strategies or market adaptation efforts.
| Time | Growth |
|---|---|
| 3 years | 1.06% |
| 5 years | 1.84% |
The average dividend growth is 1.84% over 5 years. This shows moderate but steady dividend growth.
Payout ratios provide insights into Albemarle's financial strategies. Current negative values suggest financial pressures, as the EPS-based payout ratio is -33.52%, and the FCF-based stands at a challenging -568.07%. This highlights discrepancies between profitability and cash flow allocation.
| Key figure | Ratio |
|---|---|
| EPS-based | -33.52% |
| Free cash flow-based | -568.07% |
The following metrics underscore Albemarle's cash flow health and capital deployment efficiencies. Assessing these is crucial as they highlight potential operational challenges and strategic capital allocations.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Free Cash Flow Yield | 2.54% | -4.86% | -9.72% |
| Earnings Yield | 8.04% | 9.28% | -11.66% |
| CAPEX to Operating Cash Flow | 66.13% | 162.17% | 240.11% |
| Stock-based Compensation to Revenue | 0.42% | 0.38% | 0.60% |
| Free Cash Flow / Operating Cash Flow Ratio | 33.87% | -62.17% | -140.11% |
These challenges in free cash flow yield and high CAPEX ratios indicate a potential strain on near-term liquidity.
Analyzing these leverage and liquidity metrics helps investors gauge Albemarle's ability to meet its financial obligations and sustainably manage debt.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Debt-to-Equity | 40.30% | 45.80% | 36.30% |
| Debt-to-Assets | 20.81% | 23.60% | 21.77% |
| Net Debt to EBITDA | 0.60 | 4.32 | -2.40 |
| Current Ratio | 1.89 | 1.47 | 1.95 |
| Quick Ratio | 1.13 | 0.86 | 1.19 |
| Financial Leverage | 1.94 | 1.94 | 1.67 |
The stabilization in debt levels and improvements in liquidity ratios are reassuring, but the negative net debt-to-EBITDA in 2024 requires close monitoring.
The following metrics provide insight into Albemarle's fundamental performance, analyzing profitability and efficiency in capital utilization.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity | 25.59% | 16.71% | -11.84% |
| Return on Assets | 13.22% | 8.61% | -7.10% |
| Net Margin | 27.91% | 16.36% | -21.93% |
| EBIT Margin | 34.92% | 3.77% | -29.72% |
| Research & Development to Revenue | 0.98% | 0.89% | 1.61% |
The profitability metrics show variance, highlighting periodic challenges, yet showcase investment in R&D that could fuel future growth.
| Category | Score | Visual |
|---|---|---|
| Dividend yield | 3 | |
| Dividend Stability | 4 | |
| Dividend Growth | 2 | |
| Payout Ratio | 1 | |
| Financial Stability | 2 | |
| Dividend Continuity | 5 | |
| Cashflow Coverage | 1 | |
| Balance Sheet Quality | 3 |
Albemarle Corporation holds a resilient dividend background with a commitment to shareholder returns. While facing financial obstacles highlighted by negative payout ratios and profitability challenges, the strong continuity of dividends and strategic R&D investments suggest potential for long-term growth. Cautious optimism is recommended for investors, pending further improvements in financial metrics.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.